Biosimilars: US and Europe

COVID-19 and its economic impacts have only strengthened the case for further developing a sustainable global biosimilars market. In this Insights@CromosPharma paper we explore the development of the European biosimilar market and contrast this with the US. We also look at the key challenges and opportunities facing biosimilar developers.

Download pdf

CONTACT

BD@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

News Digest – Edition 4
News Digest on Biotech and Pharma Industry. Edition 4
Сlinical trials in Poland – Country Profile 2022
News Digest on Biotech and Pharma Industry. Edition 3
Cromos Pharma Clinical Trials in Georgia
Сlinical trials in Georgia – Country Profile 2022
Lasagna’s Law and patient recruitment
Clinical Trials in Hungary – Country Profile 2022
Lasagna’s Law: Patient Recruitment and Clinical Trials
News Digest on Biotech and Pharma Industry. Edition 2
Celebrating women’s contribution to clinical research
News Digest on Biotech and Pharma Industry. Edition 1
Cromos Pharma’s “No Patients – No Payment” program explained
Cromos Pharma celebrates drug discoveries that have changed the world
Сlinical trials in the Czech Republic – Country Profile 2021
Rare disease clinical trials factsheet
Conducting Clinical Trials in Poland – Country Profile 2021
Cromos Pharma on why Central and Eastern Europe are the hottest locations for clinical trials
Free Feasibility Reports Initiative Video
Clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction: Design and Rationale
Clinical Trials in Georgia
Simple Math for Clinical Trial Success
Rare Disease Drug Development
Upcoming EU drug/device legislation: What you need to know
Reaping the benefits of a Euro-Australian collaboration for biotechs: save on costs and time
Clinical characteristics of dermatologic manifestations of COVID‐19 infection